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Abstract
A double-blind, randomized, controlled, parallel-group prospective trial was conducted to
determine whether a dose-response existed for four different levels of docosahexaenoic acid
(DHA) supplementation on the cognitive performance of infants. A total of 122 term infants were
fed one of four different formulas varying in their DHA composition (0.00%, 0.32%, 0.64% and
0.96% of total fatty acids as DHA) from birth to 12 months. The three DHA-supplemented
formulas also contained 0.64% of total fatty acids as arachidonic acid (ARA, 20:4n-6). Infants
were tested at 4, 6, and 9 months of age on a visual habituation protocol that yielded both
behavioral and psychophysiological indices of attention. Infants in all DHA+ARA-supplemented
conditions had lower heart rates than those in the unsupplemented condition; there was no dose-
response for this effect. The distribution of time that infants spent in different phases of attention
(a cognitive index derived from the convergence of behavioral and cardiac responses) varied as a
function of dosage. Infants supplemented at the two lower DHA doses spent proportionately more
time engaged in active stimulus processing than infants fed the unsupplemented formula, while
infants fed the highest dose were intermediate and did not differ from any other group.
Introduction
The central nervous system (CNS) is highly enriched in docosahexaenoic acid (DHA,
22:6n-3) and arachidonic acid (ARA, 20:4n-6), but of these two fatty acids, only brain DHA
content has been shown to vary as a result of postnatal dietary intake (1, 2). CNS DHA
accumulates rapidly during the last intrauterine trimester and in the first two years of life (3,
4). A number of randomized studies of DHA supplementation have been designed with the
intent of understanding the functional consequences of increasing postnatal DHA exposure.
The majority of these studies have measured visual acuity. In term infant studies, both
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positive (5, 6) and null (7–9) effects of postnatal supplementation have been observed, with
positive effects typically manifest as an accelerated developmental function for visual acuity
during the first year of life.
Learning and cognition are also outcomes of interest given the large amount of DHA that
accumulates in the brain, relative to other organs. Indeed DHA has been reported to affect
learning and cognition in both animals (10, 11) and humans (12, 13). However, the results of
studies using global assessments of early cognitive function (e.g., the Bayley Scales of
Infant Development, or childhood IQ tests, such as the Stanford Binet or Weschler tests) as
outcomes of long-chain polyunsaturated fatty acid (LCPUFA) supplementation or status are
mixed. Investigators have reported benefits on the Brunet-Lezine Scale (14, 15), the Bayley
Scales (16), and the Weschler Primary Preschool Scale of Intelligence (17). Null effects
have been reported with the Bayley Scales (18) and with the Stanford Binet (19). Both a
recent systematic review (20) and a meta-analysis (21) concluded that the Bayley Scales of
Infant Development are unaffected by LCPUFA supplementation.
More precise measures of cognition in infancy have long been available from techniques
developed for experimental laboratory studies (22). Indeed, measures of attention in infancy
tend to be more closely correlated with later cognitive function than outcomes on global
tests of early development (23, 24). Moreover, higher DHA exposure in utero has been
associated with first year behavior indicative of accelerated attentional development (25)
suggesting a potential value for attention as a means of evaluating the effects of LCPUFA
supplementation on cognition. Prior randomized clinical trials of postnatal DHA
supplementation have not included measures of attention. Furthermore, no previous
randomized trial has examined the possibility of a dose-response with respect to the effect of
DHA on development, thus inhibiting progress toward the establishment of a standard for
DHA intake or supplementation.
Here, we report the results of postnatal LCPUFA supplementation with 3 levels of DHA
supplementation on a specific measure of developing cognition; i.e., infant attention and
learning in a visual habituation paradigm (26). Along with behavioral indices of attention
during visual habituation, we assessed heart rate (HR) and the quality of attention through
the conjunction of HR deceleration with visual fixation, which allows the calculation of
heart-rate defined phases of attention (27). The inclusion of measures of HR within the
cognitive paradigm also allowed for a test of the effects of specific LCPUFA
supplementation in infancy on cardiac variables; the extant literature suggests that
LCPUFAs (especially omega-3 fatty acids) may affect HR and HR variability through a
number of candidate mechanisms (28, 29).
Methods
Data reported here were for planned secondary outcomes specific to one of the two sites
involved in the DIAMOND (DHA Intake And Measurement Of Neural Development) study
(registered as NCT00753818 at www.clinicaltrials.gov), a double-masked, randomized,
controlled, parallel-group prospective trial designed primarily to measure sweep visual-
evoked potential acuity. The primary outcomes of this trial were red blood cell DHA and
ARA in response to formula and visual acuity development. The results have been reported
elsewhere, and the report includes a complete description of study design, growth, formula
intake and tolerance, red blood cell DHA and ARA in response to formula, and adverse
events (30).
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The trial enrolled healthy, term, formula-fed, singleton-birth infants (37–42 weeks gestation;
2490 to 4200 grams birth weight) born in the Kansas City metropolitan area between
September 3, 2003 and September 25, 2005. Exclusion criteria included the receipt of
human milk within 24 hours of randomization, conditions known to interfere with normal
growth (e.g., low birth weight; metabolic anomalies) or development (e.g., maternal chronic
infectious, metabolic or renal disease or evidence of alcoholism or substance abuse), poor
formula intake, or intolerance to cow's milk infant formula. Informed consent was obtained
from all subjects and the study was approved by the Human Subjects Committee at the
University of Kansas Medical Center.
Design and Randomization
During the first week of life, infants were randomly assigned to one of four cow's milk-
based term infant formulas, which varied only in LCPUFA content. Control infants were fed
formula containing no DHA or ARA. Three groups received supplemented formulas varying
in DHA. One group received 0.32% of fatty acids from DHA (17 mg/100 kcal), a second
received 0.64% (34 mg/100 kcal), and a third received 0.96% (51 mg/100 kcal). All three
DHA supplemented formulas included 0.64% of fatty acids (34 mg/100 kcal) from ARA.
DHA was derived from single-cell algal oils; ARA from fungal oils (Martek Biosciences,
Columbia, MD). Blood level analyses were conducted on the four groups for DHA at 4 and
12 months of age, and have been reported elsewhere (30).
Randomization was performed by and held exclusively by the study sponsor during the
conduct of the research. Each of the four formulas had two different codes, for a total of 8
codes. All personnel recruiting infants, parents or guardians, researchers, study monitors,
and pediatricians were blind to the infants' study formula group allocation. Infants were fed
the study formulas for the first 12 months without limits. Gender was balanced across all
groups.
Procedures
Infants were evaluated at the study site at 4, 6, and 9 months of age on a visual habituation
protocol that was augmented with simultaneous measurement of HR. In visual habituation,
the infant's visual and cardiac responses are assessed to repetitive stimulus presentations; the
decline in responses to the stimulus is generally interpreted to indicate learning of the
stimulus. Details of the testing situation, stimuli, and recording of infant looking are
reported at length elsewhere (25, 31). The stimuli used in habituation tests were static color
presentations of adult faces, chosen from a set used in previous research. Infants were
habituated to one face at each visit, in a session lasting 5 to 15 minutes in length. The face
stimuli used in the study were counterbalanced across ages, so that no infant saw the same
stimulus twice.
Testing Sequence—A 20s–30s baseline period was conducted prior to the start of the
session, during which HR was collected with no stimulus present. Infants were then
habituated to static visual stimuli using an infant-controlled sequence (32), with a criterion
of two consecutive looks at a 50% decrement from the previous longest look and a “floating-
point” criterion (33). A valid fixation was defined as a look of 1 s or more in duration;
fixations were considered to be terminated when the infant looked away for 1 s or more (34).
The stimulus was removed after termination of a fixation, and a subsequent interstimulus
period of 2s ensued.
Measurement of HR—HR was measured with shielded Ag-AgCl electrodes placed on
either side of the infant's chest and grounded with an unshielded electrode on the abdomen.
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The infant's electrocardiogram (EKG) was digitized at 250 Hz sample rate. The data
acquisition interface also received input from the microcomputer that controlled the timing
and presentation of stimuli so that HR could be synchronized with stimulus events and the
coding of fixations.
Data Reduction and Statistical Treatment
The time stamp of each infant's R-wave was derived from the digitized EKG and
synchronized with time stamps from stimulus events and infant behaviors. Along with the
calculation of infant HR during the session, this protocol capitalizes on the fact that infants
typically show HR deceleration while looking. This deceleration has been used to derive
different types of attention during looking (35); the actual declerative phase is called
sustained attention (SA), and has been shown to reflect active engagement with, and
processing of, the stimulus (35). The period preceding SA reflects simple orienting (OR) to
the stimulus, and the period after SA reflects disengagement from the stimulus (attention
termination, or AT). The derivation of these phases is explicated in detail elsewhere (31).
For our purposes, the proportion of time spent in SA was the measure of interest. For
purposes of brevity, analyses for OR and AT are not shown here (they were unaffected by
Formula) but these phases are represented in Table 3 and Figure 1.
Statistical Methods—As a whole, the trial was powered for the primary outcomes of
visual acuity (30). Heart rate and looking variables from the habituation session were
subjected to mixed-model factorial analyses (using PASW Statistics 17.0, formerly SPSS)
using fixed factors of Formula (4) and Age (3). Age was entered into the model as a
repeated factor, subjects as a random factor, and covariance was left unstructured. This
analysis uses all available data in longitudinal applications, while allowing for simultaneous
age comparisons, assessment of Age × Formula interactions, and assessment of overall main
effects. An accounting of subjects from 4 to 9 months is shown in Table 1.
Results
Three primary measures were analyzed for this study: peak look (i.e., the longest look
duration observed during habituation), a behavioral measure taken from the habituation
session that is thought to reflect the relative rapidity with which the infant learned or
encoded the stimulus (32), the proportion of time spent in sustained attention (averaged
across trials), a HR-defined phase of attention, as described above, and (c) mean HR during
periods of baseline, pre-looking, and looking (also averaged across trials; the latter being
parsed by the three respective phases of attention described above).
Look Duration Measures
The analysis for peak look duration (see Table 2) showed a significant decline in look
duration with age, F(2, 100.912) = 22.542, p<.001, but no effects of formula.
Sustained Attention
Analyses of the HR-defined phase of sustained attention (also in Table 2) showed significant
main effects for both Age and Formula but no significant interactions. The proportion of
time spent in SA declined significantly with age, F(2,104.743) = 6.971, p=.001, with SA
being significantly higher in the two intermediate doses of DHA (0.32% and 0.64%) relative
to controls (p=.035 and p=..005, respectively). The highest DHA dose (0.96%) did not differ
from either controls or the two other doses, and the Age × Formula interaction did not
approach statistical significance.
Colombo et al. Page 4














As expected, infants' HR showed a consistent change with age (all ps<.001) for every
variable tested during the session; overall, HR in beats per minute (bpm) declined from 146
to 138 to 133 at 4, 6, and 9 months, respectively. In addition, lower HR was observed
consistently for all three supplemented groups, relative to controls. A summary figure (see
Figure 1) shows mean HR for the four groups across baseline, pre-looking, and looking
(including across each of the three HR-defined phases of attention). At each age, the main
effects for Formula group ranged from p<.05 to p<.01 (in no case did any two-way
interaction attain significance), with pairwise comparisons showing each of the three
supplemented groups 5 to 9 bpm lower than the unsupplemented controls.
Discussion
Positive effects of postnatal DHA supplementation in term infants are typically seen above
0.20% total fatty acids as DHA (14, 16), but concentrations of DHA in human breast milk
can vary well beyond these levels, suggesting that systematic tests of doses at higher levels
are desirable. The analyses of data from infant psychophysiological responses and on the
quality of attention at 4, 6, and 9 months showed significant and positive effects of LCPUFA
supplementation on the quality of attention in infants from 4 to 9 months of age.
There were no Formula effects or interactions on the peak look variable from habituation.
The age effect observed here for this variable has been routinely reported in prior research
(33) and is generally attributed to older infants' more rapid processing of stimuli during
habituation (26). The lack of any significant effects involving Formula here contrasts with
prior results indicating sensitivity of look duration to LCPUFA status in preterm infants or
to maternal LCPUFA status in full-terms (25, 36).
The proportion of time spent in SA, which is the phase of attention most strongly linked to
active information processing in human infants (37, 38), was increased relative to controls
in the 0.32% and 0.64% DHA doses, but not at the highest (0.96%) dose. The finding of
increased SA was observed across all ages at which the measure was taken (4, 6 and 9
months). Given that this improvement was not linearly related to DHA dose, we are inclined
to posit DHA levels as the source of the effect on SA; since SA at the highest DHA dose
was not statistically distinguishable from the two lower doses, however, the contribution of
ARA cannot be definitively ruled out, as the power of the study may be less than optimal for
comparing individual conditions to one another. If the effect is attributed to DHA, this
would represent the first indication that higher doses of DHA may not incur proportional
benefit. In a previous observational study, higher maternal DHA status at birth was found to
be associated with lower look duration in later infancy (25); within the context of those
results, SA was also observed to be lower in infants from high-DHA mothers, which is what
one would expect as look duration is reduced. However, in the previous study, DHA status
was observed to reduce look duration, in the current one LCPUFA supplementation did not.
We have observed that when look duration is reduced across or within sessions, the
proportion of SA is reduced, and is generally displaced by OR (39). This appears to be due
to the fact that OR represents a latency to decelerate that is fairly constant; in briefer looks,
OR takes up a larger proportion of looking, and essentially takes this proportion from SA.
The increase in SA in the 0.32% DHA and 0.64% DHA formula conditions is interpreted as
the maintenance of engaged cognitive processing in the context of equal amounts of looking;
we see this as a positive benefit of supplementation. It is important to note that the recent
results of a large longitudinal study show that infants who show reliable age-related
decreases in look duration while maintaining high levels of SA across the first year show
better performance on language and cognitive outcomes out to age 4 (40).
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LCPUFA supplementation also reduced infants' overall HR when measured during the
administration of the visual attention task. The main emphasis of the original study was on
dose effects for DHA; it was hypothesized that the three DHA-supplemented groups would
vary. The fact that manipulation of DHA dose covaried with the presence of ARA in the
formula (i.e., the control formula had neither DHA nor ARA) makes interpretation of this
effect complicated, as the reduction in HR (relative to the control group) was statistically
equivalent for each of the DHA dose levels. As such, we cannot definitively attribute this
effect to the sole action of either of these compounds. The positive effect of LCPUFAs on
cardiovascular health in rodents and human adults has been known for some time (41, 42),
and there have been multiple reports of reductions in HR or increased HR variability as a
result of some form of increased n-3 LCPUFA intake (43, 44).
Our finding here is also in accord with the results of a previous clinical trial of fish oil
supplementation in infants (45) and a preliminary report on an observational study of DHA
intake in infants and toddlers (Pivik RT et al. 2008 Resting heart rate in infants and toddlers:
Variations associated with early infant diet and the omega 3 fatty acid DHA. Forty-Eighth
Annual Meeting of the Society for Psychophysiological Research, October 2–4, 2008,
Austin, Texas, Poster 123), both of which report decreases in HR in relation to DHA status.
The pathways through which LCPUFAs influence heart period are not definitively known,
although candidate mechanisms include reduced oxygen consumption (46),
electrophysiological mediation of the heart rhythm (44), or various forms of autonomic
gating originating in the CNS (47, 48). The effect of lowering HR in adult populations is
viewed as a positive health outcome and has been suggested to impart positive impacts on
affective, cognitive, and behavioral outcomes (48). HR declines systematically with age
during infancy (31) so the effect may also represent the acceleration of psychophysiological
maturation.
In summary, the current findings add further experimental evidence for the positive health
and cognitive effects of LCPUFAs in neurodevelopment in human infants. Further research
will necessary to definitively dissociate the effects of AA from DHA on HR and SA; the
current work may be constrained by limited power for these particular variables. Future
reports will focus on the long-term implications of the improvements in attention observed
with moderate DHA supplementation.
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Mean HR (collapsed across age) for four formula groups at critical points of interest during
the habituation task. Squares represent 0.0% DHA/0.0% ARA (unsupplemented controls);
circles represent 0.32% DHA/0.64% ARA; triangles represent 0.64% DHA/0.64% ARA;
diamonds represent 0.96% DHA/0.64% ARA.
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Table 3
Estimated means and standard errors (in parentheses) from Age X Group analyses for infant HR (expressed in
bpm) from each segment of habituation trial. Mixed model main effects for Formula at each point shown are
as follows: Baseline, F(3,104.54) = 3.63, p=.015; Pre-Looking, F(3, 108.17) = 2.85, p=.041; F(3, 108.45) =
4.13, p=.008; OR, F(3, 105.20) = 2.87, p=.040; SA, F(3, 109.02) = 3.48, p=.019; AT, F(3, 90.96) = 3.28, p=.
024.
Age (mos)
HR During: Formula Condition 4 6 9
Baseline
0.00%DHA/0.00%ARA 150.2 (2.08) 143.0 (1.93) 135.0 (2.80)
0.32%DHA/0.64%ARA 144.4 (2.01) 136.0 (1.85) 128.0 (2.52)
0.64%DHA/0.64%ARA 149.1 (2.24) 137.5 (1.85) 137.8 (2.82)
0.96%DHA/0.64%ARA 145.1 (2.01) 136.6 (1.79) 133.1 (2.56)
Pre-Look
0.00%DHA/0.00%ARA 155.6 (2.20) 146.2 (2.06) 139.1 (3.16)
0.32%DHA/0.64%ARA 147.4 (2.12) 138.2 (1.99) 133.4 (2.85)
0.64%DHA/0.64%ARA 149.6 (2.36) 139.6 (2.19) 139.1 (3.19)
0.96%DHA/0.64%ARA 149.2 (2.12) 138.8 (1.92) 138.4 (2.88)
OR
0.00%DHA/0.00%ARA 159.1 (2.35) 147.5 (2.27) 142.1 (3.59)
0.32%DHA/0.64%ARA 149.5 (2.42) 140.1 (2.19) 136.1 (3.28)
0.64%DHA/0.64%ARA 152.9 (2.62) 140.0 (2.37) 142.3 (3.68)
0.96%DHA/0.64%ARA 150.4 (2.27) 139.5 (2.15) 141.1 (3.26)
SA
0.00%DHA/0.00%ARA 149.8 (2.18) 141.0 (2.78) 132.8 (3.12)
0.32%DHA/0.64%ARA 141.7 (2.08) 133.0 (2.72) 124.8 (2.65)
0.64%DHA/0.64%ARA 143.7 (2.35) 133.1 (3.08) 134.3 (2.88)
0.96%DHA/0.64%ARA 141.8 (2.11) 130.8 (2.67) 131.8 (2.61)
AT
0.00%DHA/0.00%ARA 159.6 (2.17) 154.5 (3.35) 142.5 (3.50)
0.32%DHA/0.64%ARA 151.5 (2.05) 142.5 (3.10) 134.1 (3.19)
0.64%DHA/0.64%ARA 154.1 (2.37) 143.4 (3.89) 142.5 (3.22)
0.96%DHA/0.64%ARA 154.2 (2.17) 138.7 (3.14) 141.8 (2.96)
Post-Look
0.00%DHA/0.00%ARA 155.9 (6.03) 149.0 (5.50) 141.2 (4.22)
0.32%DHA/0.64%ARA 138.1 (5.83) 125.4 (5.29) 132.3 (3.77)
0.64%DHA/0.64%ARA 151.0 (6.49) 140.2 (5.84) 141.4 (4.23)
0.96%DHA/0.64%ARA 134.8 (5.82) 135.5 (5.11) 140.6 (3.83)
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